Recent trial evidence and the 2018 cholesterol guidelines have reshaped lipid management. As clinicians are still learning how to incorporate the established nonstatins into the treatment of high-risk patients, two novel nonstatin agents (bempedoic acid and inclisiran) may again change the approach to lipid management.

Throughout this course, you’ll have the chance to explore the current lipids landscape and learn about the latest developments in cholesterol management.

	Certified Patient Cases Apply your knowledge of nonstatin therapies in management of ASCVD patients according to the latest guidelines and trial data. Case 1: Choosing the Appropriate LDL-C Targeted Nonstatin: 48-year-old Woman Presents to the Clinic for Follow-up on her Lipids Case 2: Choosing the Appropriate LDL-C Targeted Nonstatin: 41-year-old Man with FH Presents to the Clinic for Follow-up on his Lipids
	Self-Paced Learning Jump into this engaging eLearning curriculum to navigate the evolving lipids landscape with the current role of nonstatin therapies and explore the newest additions to the armamentarium of lipid lowering therapies. The Clinical Implications and Role in Therapy for LDL-C Targeted Nonstatins Potential Additions for Your LDL-C Toolbox
	Webinar Join expert faculty Kim Birtcher, PharmD, AACC, Christie M. Ballantyne, MD, FACC, and Anne C. Goldberg, MD as they review the latest trial results, novel mechanisms of action, and anticipated clinical implications of the newest lipid lowering therapies. Meeting On Demand

Click here to see additional Spotlight Topics in the Clinical Spotlight Series